AI assistant
Ocugen, Inc. — Director's Dealing 2019
Dec 16, 2019
32915_dirs_2019-12-16_06d6856e-b279-4ea1-b575-3e0bc7839abe.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 3 — Initial Statement of Beneficial Ownership
Issuer: Ocugen, Inc. (OCGN)
CIK: 0001372299
Period of Report: 2019-09-27
Reporting Person: Arumugham Rasappa (Chief Scientific Officer)
Holdings (Derivative)
| Security | Exercise Price | Expiration | Underlying | Shares | Ownership |
|---|---|---|---|---|---|
| Stock Options (right to buy) | $6.30 | 2027-03-22 | Common Stock (23011) | Direct | |
| Stock Options (right to buy) | $7.56 | 2027-12-15 | Common Stock (9588) | Direct | |
| Stock Options (right to buy) | $12.18 | 2028-08-13 | Common Stock (2397) | Direct | |
| Stock Options (right to buy) | $13.52 | 2028-12-07 | Common Stock (9588) | Direct |
Footnotes
F1: 15,341 Stock Options became exercisable immediately, and the remaining 7,670 Stock Options will become exercisable on March 21, 2020, subject to continued employment with Ocugen, Inc. (the "Company").
F2: 3,196 Stock Options became exercisable immediately, and the remaining 6,392 Stock Options will become exercisable 50% each on December 15, 2019 and December 14, 2020, subject to continued employment with the Company through the applicable vesting date.
F3: 799 Stock Options became exercisable immediately, and the remaining 1,598 Stock Options will become exercisable 50% each on July 23, 2020 and July 22, 2021, subject to continued employment with the Company through the applicable vesting date.
F4: The Stock Options will become exercisable 1/3 each on December 7, 2019, December 7, 2020 and December 6, 2021, subject to continued employment with the Company through the applicable vesting date.